Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2025-01-17 Regulatory Filings
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) announcing the details of an upcoming earnings call scheduled for January 23, 2025. It includes dial-in numbers and contact information for clarifications. The document does not contain any financial data or results itself, but rather serves as an invitation or notification about the earnings call event. Therefore, it is not the earnings release (ER) itself, nor a transcript (CT), but an announcement related to the earnings call. Given the filing definitions, this fits best under Call Transcript (CT) category as it relates to the earnings call event, but since it is only an invitation and not the transcript, the closest appropriate category is Regulatory Filings (RNS) as a general announcement. However, since the filing definitions include Call Transcript (CT) as full text transcript of calls, and this is only an invitation, the best fit is Regulatory Filings (RNS).
2025-01-17 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-16 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter dated January 16, 2025, addressed to stock exchanges (NSE and BSE) informing about an upcoming Board Meeting scheduled for January 23, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2024. It also mentions the closure of the trading window for insider trading compliance. The document does not contain any financial data or results itself, nor does it include a report. It is an announcement of a board meeting and related compliance information. The document length is short (2014 characters), and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-16 English
Name and Symbol Change
Regulatory Filings Classification · 100% confidence The document is a circular from the National Stock Exchange of India announcing a change in the name and symbol of a listed company, Glenmark Life Sciences Limited, effective January 20, 2025. It is an official notice related to listing information and does not contain financial data, management discussion, or report content. It is not a report or financial filing but a regulatory announcement about a listing change. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-01-14 English
Name Change
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges and regulatory bodies informing about the change of the company's name from 'Glenmark Life Sciences Limited' to 'Alivus Life Sciences Limited'. It includes a Certificate of Incorporation pursuant to the change of name issued by the Ministry of Corporate Affairs. The document does not contain financial data, management discussion, or detailed report content. It is a regulatory disclosure under SEBI Listing Regulations, specifically a notification of a corporate action (name change). The document length is 4212 characters, which is relatively short and primarily serves as an official announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-12-17 English
Shareholders meeting
Regulatory Filings
2024-11-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.